BrainScope Company is planning to introduce Ahead EU-100, a product in development to aid in the assessment of head injury, in the UK.
The Ahead EU-100 is a portable, non-invasive, point of care, non-radiation emitting medical device in development that utilizes product miniaturization and advanced signal processing methods to provide an objective assessment and categorization of brain electrical activity associated with brain injury, identifying patterns consistent with a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury.
The Ahead EU-100 consists of three main components: a hand-held device that includes software and algorithms for EEG acquisition and analysis and patient stratification, a disposable electrode headset, and a web-based capability for centralized storage and review of patient data.
In conjunction with the launch of the B-Ahead UK Clinical Trial, the company anticipates obtaining CE mark certification in the second half of 2011, which will provide European regulatory clearance to market and sell the Ahead EU-100 in the UK and throughout Europe.
In addition, BrainScope recently formed a UK subsidiary, BrainScope UK Ltd, representing the first subsidiary set up to commercialize its products outside of the US.